News
12-11-2012, 02:20 AM
Adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a large number of women with early stage HER2-positive breast cancer. But trastuzumab does not stop tumors from returning in about 25 percent of patients - and oncologists haven't been able to identify these women before treatment...
More... (http://www.medicalnewstoday.com/releases/253775.php)
More... (http://www.medicalnewstoday.com/releases/253775.php)